このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Intra-Cellular Therapies マネジメント
マネジメント 基準チェック /34
Intra-Cellular Therapies'の CEO はSharon Matesで、 May2002年に任命され、 の在任期間は 22.25年です。 の年間総報酬は$ 10.09Mで、 8.8%給与と91.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.01%を直接所有しており、その価値は$ 82.40M 。経営陣と取締役会の平均在任期間はそれぞれ5.9年と10.6年です。
主要情報
Sharon Mates
最高経営責任者
US$10.1m
報酬総額
| CEO給与比率 | 8.8% |
| CEO在任期間 | 22.3yrs |
| CEOの所有権 | 1.0% |
| 経営陣の平均在職期間 | 6yrs |
| 取締役会の平均在任期間 | 10.7yrs |
経営陣の近況
Recent updates
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business
Sep 22
Peaking Back In On Intra-Cellular Therapies
Sep 04Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 10With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For
Jul 27Intra-Cellular Brightens MDD Outlook With Caplyta Success
Jun 19Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data
Apr 16Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark
Apr 09We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Mar 17Intra-Cellular Therapies Is On Fire
Mar 11Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'
Feb 11Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues
Dec 24We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow
Nov 11Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth
Aug 07Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation
May 09After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar
Apr 17We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate
Jan 31Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans
Oct 25Intra-Cellular Therapies: What Lies Ahead
Sep 20Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug
Aug 22Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M
Aug 09We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely
Jul 09Intra-Cellular Therapies: A Dramatic Story
Jun 18Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth
Apr 03Intra-Cellular: Not Participating In A Bear Market
Mar 31Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand
Mar 08CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$84m |
| Mar 31 2024 | n/a | n/a | -US$111m |
| Dec 31 2023 | US$10m | US$892k | -US$140m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$228m |
| Dec 31 2022 | US$9m | US$849k | -US$256m |
| Sep 30 2022 | n/a | n/a | -US$298m |
| Jun 30 2022 | n/a | n/a | -US$321m |
| Mar 31 2022 | n/a | n/a | -US$304m |
| Dec 31 2021 | US$7m | US$794k | -US$284m |
| Sep 30 2021 | n/a | n/a | -US$259m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$232m |
| Dec 31 2020 | US$5m | US$767k | -US$227m |
| Sep 30 2020 | n/a | n/a | -US$207m |
| Jun 30 2020 | n/a | n/a | -US$187m |
| Mar 31 2020 | n/a | n/a | -US$160m |
| Dec 31 2019 | US$5m | US$745k | -US$148m |
| Sep 30 2019 | n/a | n/a | -US$148m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$154m |
| Dec 31 2018 | US$4m | US$723k | -US$155m |
| Sep 30 2018 | n/a | n/a | -US$145m |
| Jun 30 2018 | n/a | n/a | -US$126m |
| Mar 31 2018 | n/a | n/a | -US$106m |
| Dec 31 2017 | US$5m | US$702k | -US$98m |
報酬と市場: Sharonの 総報酬 ($USD 10.09M ) は、 US市場 ($USD 8.38M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Sharonの報酬は増加しましたが、会社は利益を上げていません。
CEO（最高経営責任者
Sharon Mates (71 yo)
22.3yrs
在職期間
US$10,086,413
報酬
Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 22.3yrs | US$10.09m | 1.01% $ 78.4m | |
| President | less than a year | US$3.53m | 0% $ 0 | |
| Executive VP & Chief Medical Officer | 6.1yrs | US$3.51m | 0.019% $ 1.4m | |
| EVP & Chief Commercial Officer | 5.9yrs | US$3.54m | 0.028% $ 2.2m | |
| Senior VP & Chief Scientific Officer | 8.8yrs | US$2.13m | データなし | |
| Vice President of Corporate Communications & Investor Relations | 10.5yrs | US$1.38m | データなし | |
| Senior VP & Chief Compliance Officer | 5.2yrs | データなし | データなし | |
| Senior Vice President | no data | データなし | データなし | |
| Senior VP & Head of Regulatory Affairs | 6yrs | データなし | データなし | |
| Senior VP of Market Access | 5.5yrs | データなし | データなし | |
| Senior VP & Head of Clinical Development | 2.4yrs | データなし | データなし |
6.0yrs
平均在職期間
61yo
平均年齢
経験豊富な経営陣: ITCIの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 11.1yrs | US$10.09m | 1.01% $ 78.4m | |
| Independent Director | 10.7yrs | US$470.51k | 0.11% $ 8.6m | |
| Lead Independent Director | 10.7yrs | US$507.58k | 0.011% $ 830.1k | |
| Independent Director | 11.1yrs | US$473.34k | 0.039% $ 3.0m | |
| Chairman of Medical Advisory Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Member of Medical Advisory Board | no data | データなし | データなし | |
| Independent Director | 2.4yrs | US$461.30k | 0.0015% $ 114.5k |
10.7yrs
平均在職期間
71yo
平均年齢
経験豊富なボード: ITCIの 取締役会 は経験豊富で 経験豊富 です ( 10.6年の平均在任期間)。